Drug Profile

Vadastuximab talirine - Seagen

Alternative Names: 33 A; Anti-CD33A targeted ADC - Seagen; SGN CD33A

Latest Information Update: 18 Dec 2023

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Seattle Genetics
Class Antineoplastics; Drug conjugates; Immunoconjugates
Mechanism of Action DNA cross linking agents

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

Yes - Acute myeloid leukaemia
New Molecular Entity Yes

Highest Development Phases

Discontinued Acute myeloid leukaemia; Myelodysplastic syndromes

Most Recent Events

14 Dec 2023 Seagen has been acquired by Pfizer
08 Oct 2020 Seattle Genetics is now called Seagen
26 Oct 2018 Discontinued - Phase-I for Acute myeloid leukaemia in USA due to safety concerns, before October 2018 (IV)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com